(Q36716669)

15 August 2017

1 reference

title

The use of interferon in renal cell carcinoma (English)

1 reference

15 August 2017

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

9 November 2022

author name string

H. B. Muss

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1724728

9 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1724728

9 November 2022

publication date

1 January 1991

1 reference

full work available at URL

15 August 2017

https://api.elsevier.com/content/article/PII:0277537991905852?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

https://api.elsevier.com/content/article/PII:0277537991905852?httpAccept=text/plain

9 November 2022

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

European Journal of Cancer

9 November 2022

published in

1 reference

15 August 2017

volume

27 Suppl 4

1 reference

15 August 2017

page(s)

S84-7

1 reference

Of historical interest. General Grant fights cancer

15 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Renal cell carcinoma: natural history and results of treatment

9 November 2022

2

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Systemic effects of hypernephroma

9 November 2022

5

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer

9 November 2022

6

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Current status of the therapy of advanced renal carcinoma

9 November 2022

7

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump

9 November 2022

10

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion.

9 November 2022

11

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

The role of biological response modifiers in metastatic renal cell carcinoma

9 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Confidence intervals for reporting results of clinical trials

9 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Interferon therapy of metastatic renal cell cancer

9 November 2022

14

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma

9 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration

9 November 2022

17

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review

9 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases

9 November 2022

19

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer

9 November 2022

20

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Improved subjective tolerability of interferon by combination with prednisolone

9 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Combination of interferon and prednisone in human cancer

9 November 2022

22

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Anti-interferon antibodies: a perspective

9 November 2022

23

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A)

9 November 2022

24

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

9 November 2022

25

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

9 November 2022

26

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: the Lyon first-year experience in 20 patients

9 November 2022

29

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study

9 November 2022

31

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors

9 November 2022

32

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity

9 November 2022

33

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study

9 November 2022

34

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma

9 November 2022

35

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma

9 November 2022

37

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon

9 November 2022

38

1 reference

https://api.crossref.org/works/10.1016/0277-5379(91)90585-2

9 November 2022

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1724728

9 November 2022

1 reference